Aarti Drugs will host an investor meeting on August 10, 2026, providing analysts and institutional investors with an opportunity to engage with company officials. The event, organized by Nirmal Bang, is scheduled to take place at Trident BKC in Mumbai from 11:00 AM to 1:00 PM. This interaction aims to facilitate dialogue based on publicly available information, ensuring transparency for market participants without disclosing any unpublished price-sensitive information (UPSI).

The company issued the intimation pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on August 4, 2026. Rushikesh Vivek Deole, Company Secretary and Compliance Officer of Aarti Drugs Limited, signed the disclosure, confirming the schedule and compliance with regulatory norms.

Meeting Details

The specific details of the scheduled interaction are outlined below:

Management emphasized that the discussions during the meet will be strictly confined to publicly available data. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company, though no such alterations have been reported as of the filing date.

Regulatory Compliance

The disclosure aligns with the mandatory requirements under Regulation 30(6) of the SEBI LODR Regulations, 2015, which mandates listed entities to inform stock exchanges about meetings with analysts or institutional investors. By proactively sharing the schedule, Aarti Drugs ensures that all market participants have equal access to the opportunity to interact with management, thereby upholding fair disclosure practices.

No unpublished price-sensitive information is intended to be discussed during these interactions. Investors are advised that any material developments arising from such meetings would be separately disclosed through official channels if they constitute price-sensitive information.

Aarti Drugs Limited has uploaded the audio recording of its quarterly earnings conference call for the quarter ended June 30, 2026 (Q1FY27), to its official website. The company also confirmed that a detailed transcript of the discussion will be shared with stock exchanges and published online in due course. This update follows the earlier intimation of the call scheduled for August 3, 2026.

Call Recording and Transcript Availability

The audio recording is now accessible to investors and analysts via the company’s website at https://www.aartidrugs.com/reports-fillings-concall-recording . The filing, dated August 3, 2026, and signed by Company Secretary & Compliance Officer Rushikesh Vivek Deole, was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Previous Conference Call Details

The earnings call, held on Monday, August 3, 2026, at 11:00 AM IST, featured senior management discussing financial performance for Q1FY27. Key participants included Joint Managing Director Harshit Savla, Whole Time Director Harit Shah, Chief Finance Officer & COO Adhish Patil, and Managing Director of Pinnacle Life Science Private Limited, Vishwa Savla.

Access Information

Participants could join the call using country-specific dial-in numbers provided by Strategic Growth Advisors Pvt. Ltd. The availability of the recording ensures broader access for stakeholders who were unable to attend the live session.